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a b s t r a c t 
The co-occurrence of aminoglycoside and β-lactam resistance was assessed in 3358 consecutive Es- 
cherichia coli clinical isolates collected in 2014 in the greater Zurich area, Switzerland. Non-susceptibility 
to at least one of the tested aminoglycosides was observed in 470/3358 E. coli strains (14%). In strains 
categorized as broad-spectrum β-lactamase (BSBL)-producers (1241/3358 isolates), extended-spectrum 
β-lactamase (ESBL)-producers (262/3358) and AmpC-producers (66/3358), resistance to aminoglycoside 
was found in 23%, 52% and 20% of the isolates, respectively. In contrast, aminoglycoside-susceptible 
strains were rarely resistant to β-lactams (33/1777, 1.9%). The genomes of 439 aminoglycoside-resistant 
E. coli were sequenced and aminoglycoside and β-lactam genotypes were analysed. The most preva- 
lent aminoglycoside resistance genes were aph(3’)-Ia (133 strains, 30.3%), aac(3)-IId (100 strains, 22.8%), 
and aac(6’)-Ib-cr (52 strains, 11.8%). The most frequent associations with β-lactam resistance genes were 
aph(3’)-Ia or aac(3)-IId with bla TEM-1 (94 and 72 strains, respectively), and aac(3)-IIa / aac(6’)-Ib-cr with 
bla CTX-M-15 /bla OXA-1 (23 strains). These results indicate a frequent association of aac(3) and aph(3’) geno- 
types with BSBL production, and a frequent co-occurrence of aac(6’) genes with ESBL production. The 
high rate of co-occurrence of aminoglycoside resistance and β-lactamase production must be considered 
in combination therapy. 
© 2020 The Authors. Published by Elsevier B.V. 
This is an open access article under the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
1. Introduction 
Aminoglycosides are an important class of bactericidal an- 
tibiotics that are frequently used, mostly in combination with 
β-lactams, to treat severe infections caused by Gram-negative 
bacteria [1] . Resistance to aminoglycosides has been increasingly 
reported, including, most worryingly, in association with that to 
other antibiotic classes, such as β-lactams and fluoroquinolones 
[2–5] . 
Resistance to aminoglycosides in Gram-negative bacteria is 
mainly due to the production of aminoglycoside-modifying en- 
zymes (AMEs) [1 , 6] or modification of the ribosome by acquired 
16S rRNA methyltransferases (RMTases) [6 , 7] . AME production is 
by far the most frequent resistance mechanism in E. coli . AMEs 
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are divided into three classes according to the reaction they 
catalyse: (i) aminoglycoside N -acetyltransferases (AAC), (ii) amino- 
glycoside O- phosphotransferases (APH) and (iii) aminoglycoside O - 
nucleotidyltransferases (ANT) [1] . AMEs can modify aminoglyco- 
sides at various sites of the drug scaffold and the enzymes are 
classified into subclasses and types according to different substrate 
profiles. For example, AAC(3) acetylates the amino group at posi- 
tion 3 of the central 4,6-di-substituted deoxystreptamine ring II, 
AAC(6’) acetylates the amino group at position 6’ of ring I and 
APH(3’) phosphorylates the hydroxyl group at position 3’ of ring 
I of the aminoglycoside. AMEs frequently modify more than one 
aminoglycoside and the same aminoglycoside can be affected by 
several enzymes. Lastly, aminoglycoside modification may not al- 
ways result in recognizable phenotypic resistance as determined 
in vitro by assessment of minimal inhibitory concentrations (MICs) 
[1 , 8] . 
Hydrolysis of β-lactams by β-lactamases is the most com- 
mon resistance mechanism to this drug class in Enterobacterales 
[6 , 9] . β-lactamases can be classified based on molecular char- 
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acteristics or functional properties. Molecular characterization 
is based on amino acid sequence and conserved motifs and di- 
vides β-lactamases into four classes (A, B, C and D) [6 , 10] . The 
functional characterization scheme, used in this work, classifies 
β-lactamases based on their substrate and inhibitor profiles [6 , 11] . 
Major functional groups include broad-spectrum β-lactamases 
(BSBL, i.e., hydrolysing penicillins and first- and second-generation 
cephalosporins), extended spectrum β-lactamases (ESBL, i.e., 
additionally hydrolysing third-generation cephalosporins and 
monobactams and inhibited by β-lactamase inhibitors), AmpC 
cephalosporinases (i.e., hydrolysing penicillins and cephalosporins), 
and carbapenemases (i.e., hydrolysing virtually all β-lactams) [6] . 
The structural genes for AMEs and β-lactamases are often part 
of mobile genetic elements carried by a variety of plasmids in 
combination with resistance genes to other drug classes, result- 
ing in multidrug-resistant isolates [9] . Particularly worrisome is the 
frequent co-occurrence of RMTases and metallo- β-lactamases [7] . 
The ever-growing problem of multidrug resistance and the need for 
carbapenem-sparing regimens to treat infections caused by ESBL- 
producing Enterobacteriaceae have revived interest in aminoglyco- 
sides and efforts to detect and identify the resistance mechanisms 
against this drug class [8 , 12] . Although there is abundant literature 
on the microbiological, clinical and epidemiological aspects of β- 
lactam resistance in Enterobacteriaceae, there is little information 
about aminoglycoside resistance. 
The aim of this study was to assess the aminoglycoside and 
β-lactam resistance rates in clinical E. coli isolated in the Zurich 
metropolitan area in 2014, and to investigate the co-occurrence of 
aminoglycoside and β-lactam resistance genes. 
2. Materials and Methods 
2.1. Clinical isolates 
All 5765 E. coli collected during 2014 from various clinical 
materials in the diagnostic laboratory of the Institute of Medi- 
cal Microbiology, University of Zurich were included in the study 
(Figure S1). When more than one E. coli was isolated from the 
same patient, only the first strain was included. If aminoglycoside- 
susceptible and -resistant strains were recovered from the same 
patient, only the first aminoglycoside-resistant isolate was stud- 
ied. Each patient was included in the analysis only once. Of the 
resulting 3358 non-duplicate E. coli , 470 had growth inhibition di- 
ameters below the cut-off of at least one of the tested amino- 
glycosides, gentamicin, tobramycin and kanamycin. A total of 461 
aminoglycoside non-wild-type strains were sequenced (Figure S1) 
and screened for the presence of aminoglycoside or β-lactam re- 
sistance genes. 
2.2. MALDI-TOF mass spectrometry identification 
MALDI-TOF MS (Bruker Daltonics, Bremen, Germany) identifica- 
tion was performed using the direct formic acid transfer method 
[13] . 
2.3. Antibiotic susceptibility testing (AST) 
AST was performed by disk diffusion according to EUCAST 
guidelines [14] . Aminoglycoside susceptibility profiles were evalu- 
ated by disk diffusion according to EUCAST epidemiological cut- 
offs (ECOFFs, gentamicin and tobramycin = 16 mm [15] ) or local 
ECOFF (kanamycin = 15 mm) [16] . A cefpodoxime cut-off of 21 
mm was used for screening of ESBL production. Carbapenemase 
production was suspected if the meropenem inhibition zone was 
below 25 mm, or if the meropenem inhibition zone was between 
25 and 28 mm and the piperacillin/tazobactam inhibition zone di- 
ameter was below 17 mm according to EUCAST [17] . Screening 
for AmpC, ESBL and carbapenemase production was performed ac- 
cording to phenotype-based algorithms described previously [18–
20] . In brief, AmpC production was suspected if cefoxitin inhibition 
zones were below 19 mm. Results were confirmed using combina- 
tion disk testing: for AmpC the difference between cefoxitin with 
and without cloxacillin was measured; for ESBL the difference was 
determined between cefotaxime/clavulanic acid vs. cefotaxime, and 
ceftazidime/clavulanic acid vs. ceftazidime. Strains resistant to any 
β-lactam, but not producing an AmpC, ESBL or carbapenemase, 
were classified as BSBL. During 2014, all 3358 E. coli were tested for 
gentamicin and tobramycin susceptibility. In addition, 3011 strains 
were tested for kanamycin susceptibility. 
2.4. Whole-genome sequencing (WGS) 
DNA libraries were prepared following the Illumina Nextera 
protocol (Illumina, San Diego, CA, USA) or the QIAseq FX DNA Li- 
brary Kit (QIAGEN AG, Hombrechtikon, Switzerland). Quality con- 
trol of the library was performed using capillary electrophoresis 
(Fragment Analyzer Automated CE System by Advanced Analytical). 
Sequencing was done on either the HiSeq 1500 or MiSeq platform 
(Illumina). 
2.5. Detection of resistance genes 
The fastq sequence files were processed by the ARIBA pipeline 
[21] and Resistance Gene Identifier 4.0.1 [22] . Resistance genes 
were identified using ARG-ANNOT (Antibiotic Resistance Gene- 
ANNOTation) [23] and CARD (Comprehensive Antibiotic Resistance 
Database) [22] . 
2.6. Sequence type (ST) analysis 
Sequence typing was performed according to the Warwick 
scheme [24] with RidomSeqsphere software 4.1.9 (Ridom GmbH, 
Muenster, Germany). 
2.7. Statistical analysis 
R (version 3.6.1) was used for statistical analysis [25] . Fisher’s 
exact test, R base version, was used. A P -value below 0.05 was con- 
sidered statistically significant. 
3. Results and Discussion 
3.1. Phenotypic aminoglycoside resistance 
ECOFFs were used to screen for aminoglycoside-non-susceptible 
E. coli as ECOFFS separate wild-type from non-wild-type popula- 
tions more accurately than clinical breakpoints (CBPs) [6 , 8 , 26] . A 
total of 5765 E. coli strains collected from various clinical materi- 
als during 2014 were analysed. When more than one E. coli strain 
was isolated from the same patient, only the first aminoglycoside- 
resistant strain, if available, was included. Of 3358 clinical iso- 
lates, 2888 (86%) were susceptible to gentamicin, tobramycin and 
kanamycin. The remaining 470 strains (14%) were resistant to at 
least one aminoglycoside ( Fig. 1 and Table 1 ). Seven aminoglyco- 
side resistance phenotypes were observed (Table S1). The resis- 
tance rate observed is somewhat higher than that reported in 2015 
by ANRESIS (8.9%), the Swiss centre for antibiotic resistance for 
Switzerland [27] , and this may be due to several reasons. First, the 
ANRESIS report includes strains isolated from hospitalized patients 
and outpatients, whereas most of the E. coli analysed in the cur- 
rent study were collected from the University Hospital of Zurich, a 
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Fig. 1. Gentamicin, tobramycin and kanamycin inhibition zone diameters [mm] of 3358 unique E. coli grouped by β-lactam resistance mechanism. BSBL, broad- 
spectrum β-lactamase; ESBL, extended-spectrum β-lactamase; WT, wild-type. AmpC, AmpC/ESBL co-producers and carbapenemase-producers were not included in the 
figure. The dashed line indicates the arithmetic mean of each distribution. The solid black line indicates the ECOFF: gentamicin and tobramycin 16 mm, kanamycin 15 mm. 
The total number (n) and the mean of each group are given at the top. 
Table 1 
Aminoglycoside non-susceptibility rates grouped by β-lactam resistance mechanism in 3358 unique E. coli . 
β-lactam resistance phenotype (Total) Wild-type (1777) BSBL (1241) ESBL (262) AmpC (66) AmpC/ ESBL (10) CPE (2) Total (3358) 
Gentamicin non-susceptible strains 15 (0.8%) 149 (12%) 95 (36.3%) 9 (13.6%) 1/10 1/2 270 (8%) 
Kanamycin non-susceptible strains 19 (1.1%) 177 (14.3%) 93 (35.5%) 7 (10.6%) 4/10 1/2 301 (9%) 
Tobramycin non-susceptible strains 12 (0.7%) 158 (12.7%) 125 (47.7%) 11 (16.7%) 4/10 1/2 311 (9.3%) 
Aminoglycoside non-susceptible strains 33 (1.9%) 282 (22.7%) 137 (52.3%) 13 (19.7%) 4/10 1/2 470 (14%) 
BSBL, broad-spectrum β-lactamase; CPE, carbapenemase-producing Enterobacteriaceae ; ESBL, extended-spectrum β-lactamase. 
tertiary care hospital. Second, there is considerable variation in the 
prevalence of aminoglycoside-resistant E. coli strains among Swiss 
regions [28] . 
Non-susceptibility to gentamicin, tobramycin or kanamycin in- 
dividually was found in 270 (8%), 311 (9.3%) and 301 (9.0%) strains, 
respectively. These rates are comparable to those reported by the 
ECDC for Europe in 2014; e.g., France, Germany and Austria have 
resistance rates to tobramycin and/or gentamicin of 7.7%, 6.9% and 
6.9% in invasive E. coli isolates, respectively [29] . 
3.2. Phenotypic resistance to β-lactams 
The rate of phenotypic β-lactam resistance was examined using 
phenotype-based algorithms [18–20] . Thus, 1777/3358 E. coli iso- 
lates (52.9%) were categorized as β-lactam wild-type (i.e., suscep- 
tible to all β-lactams), 1241 (37%) as BSBL-producers, 262 (7.4%) 
as ESBL-producers, and 66 (2%) as AmpC-producers ( Table 1 ). In 
addition, 10 strains producing ESBL/AmpC and two producing car- 
bapenemases (CPE) were detected. Reported ESBL rates in central 
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Europe for E.coli blood stream isolates (BSI) range from 7.5% to 
10.5% [30 , 31] . Although the isolates in the current study were not 
restricted to BSI, the rate of ESBL-producing strains was compara- 
ble. 
3.3. Phenotypic co-resistance to aminoglycosides and β-lactams 
Determining the phenotypic co-occurrence of aminoglycoside 
and β-lactam resistances showed only 33 of 1777 β-lactam wild- 
type strains (1.9%) were aminoglycoside-resistant ( Table 1 and Fig. 
1 ). In contrast, 282 of 1241 (22.8%) BSBL-producers were resistant 
to one or more aminoglycosides, and more than half of all ESBL- 
producers, i.e., 137 of 262 (52.3%), were aminoglycoside-resistant. 
Of the 66 AmpC-producers, 13 (19.7%) were aminoglycoside- 
resistant. Resistance to tobramycin, kanamycin and gentamicin was 
observed in 47.7%, 39.2% and 36.3% of ESBL-producers, respectively. 
Marginally different rates were found in a multicentre study con- 
ducted in Spanish hospitals in 2006: the percentage of E. coli ESBL- 
producers non-susceptible to tobramycin, kanamycin and gentam- 
icin was 31.3%, 28.2% and 25.8%, respectively [3] . Thus, on aver- 
age, aminoglycoside resistance was 10-20 times more prevalent in 
strains resistant to β-lactams compared with β-lactam-susceptible 
strains. 
3.4. Identification of aminoglycoside resistance genes 
The aminoglycoside resistance genes present in the current 
study isolates were then investigated. Altogether, the resistance 
mechanisms in 439 E. coli clinical isolates were determined by 
WGS and are given in Table 2 . Unfortunately, nine strains were 
no longer available and a further 22 strains were excluded for 
phenotype-genotype discrepancies. Overall, 31 resistance geno- 
types were found. Fourteen consisted of a single determinant spec- 
ifying an AME and 17 consisted of various gene combinations of 
AMEs and 16S rRNA methyltransferases. The most prevalent genes 
for individual AMEs were aph(3’)-Ia (133/439, 30.3%), aac(3)-IId 
(100/439, 22.8%) and aac(6’)-Ib-cr (52/439, 11.8%) (Table S2). 
In a study conducted by Miró et al . , 264 aminoglycoside non- 
susceptible E. coli clinical isolates collected in a Spanish hospital 
in 2006 were analysed and the most prevalent AME genes con- 
ferring resistance to gentamicin, tobramycin and amikacin were 
aph(3’)-Ia (13.9%), aac(3)-IIa (12.4%), and aac(6’)-Ib (4.2%) [32] . In- 
terestingly, despite the different criteria used to select the strains 
(ECOFF vs. CBP), the relative prevalence of the resistance mecha- 
nisms was similar to that in the current study. In another work in 
2009, the most frequent AMEs in a collection of 105 E. coli resistant 
or intermediately resistant to gentamicin and/or tobramycin were 
AAC(3)-II (66.7%) and AAC(6’)-Ib (10.2%) [33] . Of note, in the latter 
work neither the susceptibility to kanamycin nor the presence of 
the aph(3’)-I gene were investigated. 
3.5. Co-occurrence of aminoglycoside and β-lactam resistance genes 
The presence of β-lactam resistance genes was investigated 
in the 439 aminoglycoside non-susceptible E. coli ( Table 2 ). Due 
to their small numbers, 11 AmpC and 4 ESBL/AmpC-producers 
were not included in Fig. 2 and will not be discussed further. 
Fig. 2 shows the co-occurrence of aminoglycoside and β-lactam 
resistance genes in 424 strains classified as β-lactam wild-type, 
or BSBL- or ESBL-producers (Fisher’s exact test P = 0.0 0 04998). 
Based on genotypic data, the isolates were grouped by amino- 
glycoside resistance mechanism conferring the same inferred re- 
sistance phenotype ( Table 3 ). Thus, all strains only carrying an 
aph(3’) gene were classified as kanamycin-resistant [34] . Strains 
harbouring an aac(3’) gene were considered as resistant to gen- 
tamicin, kanamycin and tobramycin [8] . Resistance to kanamycin, 
tobramycin and amikacin was inferred from the presence of an 
aac(6’) gene [6 , 8] . 
Most isolates producing APH(3’)-Ia or AAC(3)-II alone were 
BSBL-producers; 107/132 (81.1%) and 96/135 (71.1%) respectively, 
and mostly associated with TEM-1; n = 97 and 94, respectively. In 
strains with AME combinations without AAC(6’) or RMTases, the 
large majority were BSBL-producers (29/34, 85.3%). These combi- 
nations were predominantly composed of aac (3) and aph (3’) genes. 
Again, the most prevalent β-lactam resistance mechanism was 
TEM-1 (n = 28). 
In contrast, most strains harbouring an aac(6’)-Ib alone were 
ESBL-producers; 32/50 (64%). These were mostly CTX-M-15/OXA- 
1 co-producers (n = 19). A further 18/50 (36%) strains produced a 
BSBL, of these all but one produced OXA-1. No strain was β-lactam 
wild-type. Within the 73 isolates with AME combinations including 
AAC(6’) or RMTases, the largest proportion were ESBL-producers 
(57/73, 78.1%), with CTX-M-15/OXA-1 prevailing (n = 31). Another 
16 of 73 (21.9%) strains produced BSBL, these were mostly co- 
expressing TEM-1 and OXA-1. Again, no strain was β-lactam wild- 
type. 
The common association of AAC(6’)-Ib-cr enzymes with CTX- 
M/OXA-1 was intriguing, prompting more detailed study of this 
correlation ( Fig. 3 and Table S4). Of 121 AAC(6’)-Ib-cr-producing 
strains only 9 did not contain an OXA-1. Dismissing TEM-1 and 
AAC(3)-II, the most frequent combinations were AAC(6’) and β- 
lactamases CTX-M-15/OXA-1/AAC(6’)-Ib-cr (62/121, 51.2%), OXA- 
1/AAC(6’)-Ib-cr 26 (23.1%) and CTX-M-1/OXA-1/AAC(6’)-Ib-cr 18 
(14.9%) (Table S4). This frequent trio, CTX-M-15/OXA-1/AAC(6’)-Ib- 
cr, confers broad-spectrum resistance towards aminoglycosides, β- 
lactams and fluoroquinolones [35 , 36] . 
In a previous a study, 105 of 257 E. coli isolates resistant 
to amoxicillin/clavulanic acid were also resistant to at least one 
aminoglycoside [2] . Of 15 strains producing TEM-1 alone, eight car- 
ried aph(3’)-Ia , four carried aac(3)-IIa and one isolate harboured 
ant(2”)-Ia . Among 30 OXA-1 producing strains, four harboured an 
aac(6’)-Ib gene and three a combination of aac(6’)-Ib and aph(3’)- 
Ia . Contrary to the current findings, in 21/30 strains the OXA-1 
enzyme was associated with an ANT(2”)-Ia. Curiously, in strains 
carrying a combination of ESBL and OXA-1, co-occurrence with 
AAC(6’)-Ib was found in 23/24 strains. Although these observa- 
tions point to an association of β-lactam and aminoglycoside re- 
sistance mechanisms, the full extent of this association can only 
be assessed by studying large numbers of corresponding isolates 
by WGS, as in the current study. 
3.6. Co-localization of aminoglycoside and β-lactam resistance genes 
To address whether the described resistance mechanisms 
are located on a common mobile element, long-read sequenc- 
ing is necessary. Although we do not have this data, the car- 
riage of aac(6’)-Ib-cr, bla CTX-M-1/9/15 , bla TEM-1 , and bla OXA-1 on IncF 
plasmids has been well established, particularly in association 
with FII, FIA and FIB replicons [37] . Incorporation of aac(6’)- 
Ib-cr / bla CTX-M-15 / bla OXA-1 in an IncFII plasmid is common [36] . 
This probably explains the high co-occurrence of CTX-M-15/OXA- 
1/AAC(6’)-Ib-cr observed in the current study. Similar multidrug- 
resistance plasmids, encoding combinations of TEM-1 with AAC(3) 
and/or APH(3’), may be responsible for most co-occurrences in this 
study. 
3.7. Co-evolution of aminoglycoside and β-lactam resistance 
The pattern of co-resistance described here is puzzling. In 
general, the prevalence and co-occurrence of resistance mecha- 
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Fig. 2. Co-occurrence of β-lactam and aminoglycoside resistance genes. BSBL, broad-spectrum β-lactamase; ESBL, extended-spectrum β-lactamase; WT, wild-type. The 
aminoglycoside resistance mechanism(s) based on WGS data are indicated at the top. The heights of the columns reflect the percentages of β-lactam resistance mechanisms 
co-occurring within each aminoglycoside resistance group. The numbers at the base of each column indicate the number of strains per category. Eleven AmpC and four 
AmpC/ESBL producing strains were not included in this figure. 
Table 3 
The most common aminoglycoside- 
modifying enzymes in this study and their 
respective spectra of activity [ 1 , 8 ] 
ARM Aminoglycosides modified 
APH(3’) KAN 
AAC(3) KAN, GEN, TOB 
AAC(6’) KAN, TOB, AMK 
RMTases KAN, GEN, TOB, AMK 
ARM: aminoglycoside resistance mecha- 
nism, AMK: amikacin, GEN: gentamicin, 
TOB: tobramycin, KAN: kanamycin. 
active against the first marketed aminoglycosides (gentamicin, to- 
bramycin and kanamycin), such as APH(3’)-I [34 , 38] and AAC(3)- 
II [34 , 38] , were often found in association with BSBLs, which 
confer resistance towards first-generation β-lactams [6 , 39] . In- 
deed, strains resistant to first-generation BSBLs, such as cephalotin, 
were frequently resistant to gentamicin and tobramycin [40–42] . 
In contrast, AAC(6’)-Ib, which causes decreased susceptibility to 
amikacin [6 , 8] , an aminoglycoside marketed much later than gen- 
tamicin or tobramycin [12] , was mostly found in combination with 
ESBL. A marked increase of amikacin resistance-conferring en- 
zymes, mainly AAC(6’), was seen during the 1980s in regions using 
amikacin [43] . This coincides with the introduction of ESBLs [39] , 
followed by the emergence and spread of ESBL-producing strains 
[11 , 39] . 
Thus, the evolution of co-occurrence of aminoglycoside and β- 
lactam resistance mechanisms is ongoing. Beginning in the 1960s 
with APH(3’) and AAC(3) associated with BSBLs, this was followed 
by AAC(6’) associated with ESBLs in the 1980s, and more recently 
by RMTases associated with carbapenemases [7 , 44 , 45] . The latter 
two mechanisms confer resistance to virtually all β-lactam and 
aminoglycoside antibiotics currently available in clinical practice, 
including plazomicin, the most recently developed aminoglycoside 
antibiotic [46] . 
3.8. Sequence types 
To determine whether clonal spread is involved in the co- 
occurrence of resistance described, the sequence types (STs) of 
the E. coli genomes were analysed. This revealed a wide diver- 
sity of 76 STs (Table S3). The most abundant, ST131, was found in 
124 strains associated with several β-lactam and aminoglycoside 
resistance genes. The most frequent genotypes were aac(3)-IId / 
bla TEM-1 (n = 27), aac(3)-IIa/aac(6’)-Ib-cr / bla CTX-M-15 / bla OXA-1 (n = 18) 
and aac(6’)-Ib-cr / bla CTX-M-15 / bla OXA-1 (n = 17). STs 69, 141, 10, 1193, 
88, 58, 648 and 354 occurred at least 10 times each. 
3.9. Conclusions 
In conclusion, aminoglycoside resistance and the prevalence 
of AMEs in E. coli in the greater Zurich area are comparable 
to reports from other countries, such as Spain, Poland [4] and 
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Fig. 3. Co-occurrence of AAC(6’)-Ib-cr and β-lactamases. 121 strains encoded an AAC(6’)-Ib-cr. All AAC(3)-II enzymes were grouped to facilitate an overview. β-lactamases 
occurring only once were grouped as “Other”. The numbers at the base of each column indicate the number of strains per category. Detailed information about each 
combination is available in Table S4. 
Norway. To the best of our knowledge this study is the first 
to examine the co-occurrence of β-lactamase and AME genes 
by WGS. Non-susceptibility to aminoglycosides was caused by 
a remarkable variety of AMEs and was predominantly due to 
aph(3’)-Ia, aac(3)-II and aac(6’)-Ib-cr , which are mostly associated 
with various types of β-lactamases. Non-susceptibility to amino- 
glycosides was rarely found in β-lactam-susceptible clinical iso- 
lates of E. coli. The frequent co-occurrence of AMEs/RMTases con- 
ferring resistance to all aminoglycosides available needs care- 
ful consideration, particularly for ESBL/carbapenemase-producing 
Enterobacteriaceae . 
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